Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphoma

2008205 citationsJournal Article

Authors

Stephen M. Ansell · Mayo Clinic

David J. Inwards · Mayo Clinic

Kendrith M. Rowland · Community Cancer Center

Patrick J. Flynn · Metro-Minnesota Community Oncology Research Consortium

Roscoe F. Morton · Iowa Oncology Research Association

Dennis F. Moore · Wichita Clinic

Scott H. Kaufmann

Abstract

Single-agent temsirolimus at a dose of 25 mg weekly is an effective new agent for the treatment of MCL. The 25-mg dose level retained the antitumor activity of the 250-mg dose with less myelosuppression. Further studies of temsirolimus in combination with other active drugs for MCL and other lymphoid malignancies are warranted.

Topics & Keywords

Lymphoma Diagnosis and Treatment Viral-associated cancers and disorders Chronic Lymphocytic Leukemia Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 113, Issue 3, pp. 508-514

DOI: 10.1002/cncr.23580

Field-Weighted Citation Impact: 16.81